# PATENT COOPERATION TREATYCOPY SUBMITTED IN IDS

See item 4 below

Priority date (day/month/year)

18 May 2005 (18.05.2005)

## **PCT**

#### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

FOR FURTHER ACTION

International filing date (day/month/year)

18 May 2006 (18.05.2006)

International Patent Classification (8th edition unless older edition indicated)

	THE UNIVERSITY OF TOKUSHIMA					
1.	This international preliminary rep International Searching Authority	ort on patentability (Chapter I) is issued by the International Bureau on behalf of the under Rule 44 $bis$ . I(a).				
2.	This REPORT consists of a total	of 5 sheets, including this cover sheet.				
		see to the written opinion of the International Searching Authority should be read as a reference port on patentability (Chapter I) instead.				
3.	This report contains indications relating to the following items:					
	Box No. I	Basis of the report				
	Box No. II	Priority				
	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability				
	Box No. IV	Lack of unity of invention				
	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
	Box No. VI	Certain documents cited				
	Box No. VII	Certain defects in the international application				
	Box No. VIII	Certain observations on the international application				
4.		mmunicate this report to designated Offices in accordance with Rules $44bis.3(c)$ and $93bis.1$ but akes an express request under Article $23(2)$ , before the expiration of $30$ months from the priority				

Date of issuance of this report 19 November 2007 (19.11.2007) Authorized officer

e-mail: pt08.pct@wipo.int

Masashi Honda

Facsimile No. +41 22 338 82 70 Form PCT/IB/373 (January 2004)

The International Bureau of WIPO 34, chemin des Colombettes

1211 Geneva 20, Switzerland

Applicant's or agent's file reference

See relevant information in Form PCT/ISA/237

C1-A0505P
International application No.

PCT/JP2006/309890

	TENT COOPER	ATION TE	CEATY RA			
From the INTERNATIONAL SEARCHING AUTHOR	ITY		NSI			
To:			PCT PCT			
		INTER	WRITTEN OPINION OF THE NATIONAL SEARCHING AUTHORITY			
		(PCT Rule 43his.1)				
		Date of mailing (day/month/ye				
Applicant's or agent's file reference		FOR FURTHER ACTION				
C1-A0505P		See paragraph 2 below				
International application No.	International filing date	day/month/year				
PCT/JP2006/309890	18.05.2006		18.05.2005			
International Patent Classification (IPC) or both A61K39/395 (2006.01), A61P1/16 (2006.01), A6	A61K38/21(2	006.01)				
THE UNIVERSITY OF TOKUSHIMA						
1 This opinion contains indications rela	ting to the following items	e:				
Box No. I Basis of the	Box No. I Basis of the opinion					
Box No. II Priority	Box No. II Priority					
Box No. III Non-establi	Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability					
Box No. IV Lack of unit	Box No. IV Lack of unity of invention					
Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
Box No. VI Certain doc	uments cited					
Box No. VII Certain defe	ets in the international app	plication				
Box No. VIII Certain obse	Box No. VIII Certain observations on the international application					
2. FURTHER ACTION						
If a demand for international preliminary examination is made, this opinion will be considered to be a switten opinion of the Irremational Preliminary Examining Authority (PIEA') recept that this does not apply where the applicance thooses an Authority othe than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be a considered.						
If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Fort PUTISA/220 or before the expiration of 22 months from the priority date, whichever expires later.						
For further options, see Form PCT/ISA/220.						
For further details, see notes to Form PCT/ISA/220.						
Name and mailing address of the ISAJP	Date of completion	of this opinion	Authorized officer			
Facsimile No.			Telephone No.			

### **COPY SUBMITTED IN IDS**

### WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/JP2006/309890

Box No. I Basis of this opinion
L. With regard to the language, this opinion has been established on the basis of:  the international application in the language in which it was filed the translation of the international application into translation translation for the purposes of international search (Rule 12.3(a) and 23.1(b)).
2. With regard to any nucleotide and/or unino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been catabilished on the basis of:  a type of material  a sequence listing  table(s) related to the sequence listing  b. format of material  on paper  in electronic form  c. time of fling/furnishing  contained in the international application as filed  filed together with the international application in electronic form  thresholds absoegneedly to this Authority for the purposes of search  In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filled to furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as
filed or does not go beyond the application as filed, as appropriate, were furnished.  4. Additional comments:

#### WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.

							,,,,
	Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
I. Statement							
Novelty (N	D	Claims					YES
			1-13				_ NO
Inventive s	tep (IS)	Claims					YES
		Claims	1-13				No
Industrial a	applicability (IA)	Claims	1-13				YES
		Claims					NO

#### 2. Citations and explanations:

The following documents have been shown in the ISR.

Document 1: Dinara Daniel et al., Pathway of Apoptosis Induced in Jurkat T Lymphoblasts by Anti-HLA Class I Antibodies, Human Immunology, Vol. 65, pages 189 to 199, 2004 (see, particularly, page 197, left column, line 1 to right column, line 8)

Document 2: Giuliana Cangemi et al., IFN-α mediates the up-regulation of HLA class I on melanoma cells without switching proteasome to immunoproteasome, International Immunology, Vol. 15, No. 12, pages 1415 to 1421, 2003 (see, particularly, page 1416, left column, lines 22 to 24) Document 3: O.R.Burrone et al., Stimulation of HLA-A, B, C by IFN-α. The derivation of Molt 4 variants and the differential expression of HLA-A, B, C subsets, The EMBO Journal, Vol. 4, No. 11, pages 2855 to 2860, 1085 (see, particularly, page 5, Table L)

Document 4: Naoki Kimura et al., 2D7 diabody bound to the a2 domain of HLA class I efficiently induced caspase-independent cell death against malignant and activated lymphoid cells, Biochemical and Biophysical Research Communications, Vol. 325, pages 1201 to 1209, 2004

Document 5: Laurent Genestier et al., Fas-Independent Apoptosis of Activated T Cells Induced by Antibodies to the HLA Class I (21 Domain, Blood, Vol. 90, No. 9, pages 3629 to 3639, 1997

Document 1 describes that the anti-HLA class I antibody is useful for inducing cell death to treat the tumor and that since expression of HLA is reduced in the tumor, expression of these tumor tissue compatible conjugates should be restored by a cytokine such as interferon \( \chi \).

Accordingly, document I can be considered to describe that the interferon is used in combination for enhancing the cell death induction action of the anti-IILA class I antibody when the anti-IILA class I antibody is used as a medicine for inducing cell death to treat the tumor.

Therefore, the subject matters of claims 1-13 of this international application do not appear to be novel or to involve an inventive step in view of document 1.

In this connection, claims 1-13 do not describe that interferon  $\alpha$  is used as an interferon and a specific antibody is used as the anti-HLA class I antibody, but documents 2 and 3 each describe that interferon  $\alpha$  up-regulates expression of HLA class I on the cell as interferon  $\gamma$  does, and documents 4 and 5 each describe that various kinds of HLA class I antibodies disclosed in the specification of this international application induce cell death in the tumor. Therefore, these aspects are obvious to a person skilled in the art although they are specified in the claims from documents 1-5

### **COPY SUBMITTED IN IDS**

#### WRITTEN OPINION OF THE NTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/JP2006/309890

INTERNATIONAL SEAL	PCT/JP2006/309890	
Supplemental Box		
In case the space in any of the preceding boxes Continuation of: Int.Cl.	is not sufficient.	
A61P17/06(2006.01),	A61P21/04(2006.01),	
A61P25/00(2006.01),	A61P29/00(2006.01),	
A61P35/00(2006.01),	A61P35/02(2006.01),	
A61P37/02(2006.01),	A61P43/00(2006.01)	